Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.AI Announces Increase in Revenue Growth for Arway with Map D Acquisition (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Regeneron Pharmaceuticals Inc REGN

Healthcare Biotechnology
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases... see more

Current News (NDAQ:REGN)

Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem

PR Newswire 7 days ago

Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem

GlobeNewswire 7 days ago

REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

ACCESS Newswire 8 days ago

Regeneron Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN

ACCESS Newswire 8 days ago

REGN DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action - REGN

Newsfile 8 days ago

Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

ACCESS Newswire 8 days ago

FINAL REMINDER REGN DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Regeneron Pharmaceuticals, Inc. Investors to Participate in the Class Action Lawsuit

Newsfile 8 days ago

Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) - March 10, 2025 Deadline to Join - Contact Levi & Korsinsky

ACCESS Newswire 9 days ago

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals

Newsfile 9 days ago
View More News ››

Opinion & Analysis (NDAQ:REGN)

Regeneron Shares Rise 10% on Advances in its Novel COVID-19 Antibody Program

Streetwise Reports March 18, 2020

Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation

Streetwise Reports September 24, 2019

Phase 3 trial for Inovio's VGX-3100 in cervical dysplasia gets FDA go-ahead

The Life Sciences Report June 16, 2017

Inovio moves forward on brain cancer and cancers caused by HPV; Zika and Ebola vaccines also advance

The Life Sciences Report May 18, 2017

Why the election is not as relevant to drug stocks as you might believe

The Life Sciences Report November 4, 2016

Let volatility power your micro-cap biotechs

The Life Sciences Report April 28, 2016
View More Opinion ››

Bullboard Posts (NDAQ:REGN)

REGN: Antibodies and Disruption

Regeneron’s monoclonal antibodies are changing the game, and MYNZ is disrupting diagnostics in the best way possible. Innovation rules.
Trader19Swift - November 26, 2024

REGN Price Target Alert: $1,077.00. Issued by Leerink Partne

News; $REGN REGN Price Target Alert: $1,077.00. Issued by Leerink Partners2024-09-24 07:00:09 ET David Risinger from Leerink Partners...
whytestocks - September 24, 2024

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): A Diversified

http://beyondspx.com/2024/07/31/regeneron-pharmaceuticals-inc-nasdaqregn-a-diversified-powerhouse-delivering-consistent-growth/
MikeTester - August 2, 2024

Just added REGN

Just added 1/2 position of REGN.   Will add a few more next month.
Mmb060 - April 20, 2023

Bonvoyage12.....Lying Pumper

Ignore this clown as he posts lies trying to mislead investors about the actual state of the company...he also posts this same BS on...
Mil_Man54 - December 26, 2020

Vaccine Stocks - Can the President Overrule the FDA?

An approval cycle that typically takes years is being expedited. In the case of the 2020 pandemic, the FDA  has shortened standard...
schoolofrock - October 7, 2020
View more Bullboard ››

Coppernico Metals Inc.

Coppernico Metals Inc.

Coppernico is a mineral exploration company focused on creating value for shareholders and stakeholders through diligent ...
View More »